These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

148 related articles for article (PubMed ID: 35688463)

  • 1. Sample size calculation for randomized selection trials with a time-to-event endpoint and a margin of practical equivalence.
    Dehbi HM; Embleton-Thirsk A; McCaw ZR
    Stat Med; 2022 Sep; 41(20):4022-4033. PubMed ID: 35688463
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Sample size calculation in randomised phase II selection trials using a margin of practical equivalence.
    Dehbi HM; Hackshaw A
    Trials; 2020 Mar; 21(1):301. PubMed ID: 32228674
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Safety and Efficacy of Imatinib for Hospitalized Adults with COVID-19: A structured summary of a study protocol for a randomised controlled trial.
    Emadi A; Chua JV; Talwani R; Bentzen SM; Baddley J
    Trials; 2020 Oct; 21(1):897. PubMed ID: 33115543
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Bayesian methods for setting sample sizes and choosing allocation ratios in phase II clinical trials with time-to-event endpoints.
    Cotterill A; Whitehead J
    Stat Med; 2015 May; 34(11):1889-903. PubMed ID: 25620687
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Designing clinical trials with (restricted) mean survival time endpoint: Practical considerations.
    Eaton A; Therneau T; Le-Rademacher J
    Clin Trials; 2020 Jun; 17(3):285-294. PubMed ID: 32063031
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Using the geometric average hazard ratio in sample size calculation for time-to-event data with composite endpoints.
    Cortés Martínez J; Geskus RB; Kim K; Melis GG
    BMC Med Res Methodol; 2021 May; 21(1):99. PubMed ID: 33957892
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Sample size calculation for cluster randomization trials with a time-to-event endpoint.
    Li J; Jung SH
    Stat Med; 2020 Nov; 39(25):3608-3623. PubMed ID: 33463748
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Sample size calculation for two-arm trials with time-to-event endpoint for nonproportional hazards using the concept of Relative Time when inference is built on comparing Weibull distributions.
    Phadnis MA; Mayo MS
    Biom J; 2021 Oct; 63(7):1406-1433. PubMed ID: 34272897
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Two-stage screened selection designs for randomized phase II trials with time-to-event endpoints.
    Wu J; Pan H; Hsu CW
    Biom J; 2022 Oct; 64(7):1207-1218. PubMed ID: 35661226
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Generalized optimal design for two-arm, randomized phase II clinical trials with endpoints from the exponential dispersion family.
    Jiang W; Mahnken JD; He J; Mayo MS
    Pharm Stat; 2016 Nov; 15(6):459-470. PubMed ID: 27511063
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Design of phase III trials with long-term survival outcomes based on short-term binary results.
    Bofill Roig M; Shen Y; Gómez Melis G
    Stat Med; 2021 Aug; 40(18):4122-4135. PubMed ID: 33942352
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Practical help for specifying the target difference in sample size calculations for RCTs: the DELTA
    Cook JA; Julious SA; Sones W; Hampson LV; Hewitt C; Berlin JA; Ashby D; Emsley R; Fergusson DA; Walters SJ; Wilson EC; MacLennan G; Stallard N; Rothwell JC; Bland M; Brown L; Ramsay CR; Cook A; Armstrong D; Altman D; Vale LD
    Health Technol Assess; 2019 Oct; 23(60):1-88. PubMed ID: 31661431
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Multiplicity Adjustment and Sample Size Calculation in Clinical Trials with Multiple Endpoints: An Industry Survey of Current Practices in Japan.
    Sakamaki K; Morita Y; Iba K; Kamiura T; Yoshida S; Ogawa N; Suganami H; Tsuchiya S; Fukimbara S
    Ther Innov Regul Sci; 2020 Sep; 54(5):1097-1105. PubMed ID: 32030692
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Choosing and changing the analysis scale in non-inferiority trials with a binary outcome.
    Li Z; Quartagno M; Böhringer S; van Geloven N
    Clin Trials; 2022 Feb; 19(1):14-21. PubMed ID: 34693789
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Comparison of three sample size calculation methods for non-inferiority vaccine trials with multiple continuous co-primary endpoints.
    Yang J; Li J; Wang S; Luo L; Liu P
    Hum Vaccin Immunother; 2019; 15(1):256-263. PubMed ID: 30273507
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Multiple-arm superiority and non-inferiority designs with various endpoints.
    Chang M
    Pharm Stat; 2007; 6(1):43-52. PubMed ID: 17323311
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Power and sample size calculations for cluster randomized trials with binary outcomes when intracluster correlation coefficients vary by treatment arm.
    Kennedy-Shaffer L; Hughes MD
    Clin Trials; 2022 Feb; 19(1):42-51. PubMed ID: 34879711
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Some Issues of Sample Size Calculation for Time-to-Event Endpoints Using the Freedman and Schoenfeld Formulas.
    Abel UR; Jensen K; Karapanagiotou-Schenkel I; Kieser M
    J Biopharm Stat; 2015; 25(6):1285-311. PubMed ID: 25629760
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Design of non-inferiority randomized trials using the difference in restricted mean survival times.
    Weir IR; Trinquart L
    Clin Trials; 2018 Oct; 15(5):499-508. PubMed ID: 30074407
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Sample size calculation for clustered survival data under subunit randomization.
    Li J; Jung SH
    Lifetime Data Anal; 2022 Jan; 28(1):40-67. PubMed ID: 34716530
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.